Argos reports AGS-003 combination therapy trial data

31st January 2012 (Last Updated January 31st, 2012 18:30)

Argos Therapeutics' Arcelis immunotherapy, AGS-003, in combination with sunitinib has showed a correlation between anti-tumour memory T cell responses and overall survival in Phase 2 study in patients with advanced renal cell carcinoma (RCC).

renal cell carcinomaArgos Therapeutics' Arcelis immunotherapy, AGS-003, in combination with sunitinib, has showed a correlation between anti-tumour memory T-cell responses and overall survival in a Phase 2 study in patients with advanced renal cell carcinoma (RCC).

The open-label Phase 2 trial of AGS-003 along with sunitinib was conducted in patients with newly diagnosed, unfavourable-risk, metastatic clear cell RCC, intended to stimulate the proliferation and multi-functionality of CTLs targeted directly at the autologous RCC tumour antigens.

The study results demonstrated that AGS-003 with sunitinib overcame the immunosuppressive environment of RCC and induced a tumour-specific multi-functional memory CTL response.

"We believe that the high resolution immune monitoring analysis of the Phase 2 study of AGS-003 and sunitinib represents the first time that pattern recognition algorithms originally developed for gene microarray datasets have been applied to an immunologic dataset to identify immune correlates to clinical outcome," said Charles Nicolette, Argos Therapeutics Research and Development chief scientific officer and vice president.

"The multiparametric flow cytometry data from the study that we analyzed demonstrated that the combination of AGS-003 and sunitinib induced tumor-specific multi-functional memory CTL that were statistically significant correlates to overall survival in the study, thereby supporting the intended mechanism of action of AGS-003."

Arcelis is the company's proprietary technology for personalising RNA-loaded dendritic cell immunotherapies and to challenge the genetic profile of each patient's disease and the genetic mutations of that disease.

Using biological components from each patient, Arcelis-based immunotherapies utilise the patient's dendritic cells to activate an immune response specific to the patient's disease.

The findings from the study were presented at the Global Technology Community's (GTC) 4th Immunotherapeutics and Immunomonitoring Conference in San Diego, US.

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialisation of fully personalised immunotherapies for the treatment of cancer and infectious diseases.

Image: Micrograph of the most common type of renal cell carcinoma on right of the image; non-tumour kidney is on the left of the image. Photo: Nephron.